DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Zepbound (tirzepatide) for chronic weight management and OSA with obesity. State telehealth scope, insurance coverage, and verified providers serving Florida residents.
For weight-loss indication, Florida Medicaid coverage is excludes. No weight-loss-only Medicaid coverage. T2D PA standard. Zepbound requires the weight-loss PA pathway; review Florida Medicaid criteria carefully.
Most Florida commercial plans cover Zepbound with prior authorization. PA criteria typically require BMI ≥ 30 (or ≥ 27 with comorbidity) for weight-loss-indicated drugs, or T2D diagnosis with metformin trial for diabetes-indicated drugs. Step therapy requirements vary by plan.
White-glove telehealth focused on speed and ease. Strongest pick for patients paying cash who want a fast time-to-prescription path with minimal friction.
Direct-to-consumer compounded semaglutide subscription. Affordable but trades FDA-approval status for price predictability.
Compounded GLP-1 telehealth with consistent monthly pricing. Best for patients who want compounded options without per-dose price escalation.
If insurance denies, the Florida cash-pay route is LillyDirect vials ($349-499/mo depending on dose). Available nationally; ships to Florida residents through manufacturer-direct fulfillment.
Editorial summary. Florida licensure and insurance rules change quarterly; confirm with your prescriber and plan before relying on any single source. Affiliate disclosure: we earn commission on outbound clicks to provider partners.